Impact of treatment compliance in chronic hepatitis B
10.3760/cma.j.cn501113-20201201-00635
- VernacularTitle:依从性影响慢性乙型肝炎的治疗
- Author:
Menglan WANG
1
;
Enqiang CHEN
Author Information
1. 四川大学华西医院感染性疾病中心，成都 610041
- Keywords:
Chronic hepatitis B;
Adherence;
Nucleotide drugs
- From:
Chinese Journal of Hepatology
2022;30(11):1266-1269
- CountryChina
- Language:Chinese
-
Abstract:
The incidence rate of chronic hepatitis B remains high in China. Antiviral therapy can significantly reduce the risk of progressive liver disease and hepatocellular carcinoma in patients with chronic hepatitis B. However, all current antiviral treatments can only inhibit HBV replication and not completely eliminate the hepatitis B virus, so antiviral therapy for chronic hepatitis B is probably a long-term or even lifelong treatment. Antiviral therapy compliance is essential for achieving long-term clinical benefits and preventing nucleot(s)ide drugs resistance. Herein, we analyzed the relevant factors of antiviral therapy compliance and their impact on CHB treatment and explored feasible programs that can improve compliance with nucleot(s)ide drug treatment by conducting a literature search using PubMed and Scopus with search terms including hepatitis B, compliance, nucleot(s)ide drugs, antiviral therapy, viral suppression, and drug resistance.
